Clinical trial • Phase I • Oncology

Clinical trial in Advanced solid tumors

Phase I trial for Advanced solid tumors. open-label, none/not specified-controlled, adaptive. 200 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Advanced solid tumors
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
15-03-2025
First CTIS Authorization Date
08-07-2025

Trial design

open-label, none/not specified-controlled, adaptive Phase I trial across 17 sites in France, Italy, Belgium and others.

Open Label
Yes
Comparator
None/Not specified
Adaptive
True - dose escalation and expansion design; no specific adaptive rules, interim analyses or stopping rules provided in source
Single Multiple Or Escalation Dose Combined
Yes
Target Sample Size
200

Eligibility

Recruits 200 Vulnerable population not selected; no special consent/assent handling described..

Vulnerable Population
Vulnerable population not selected; no special consent/assent handling described.

Recruitment

Planned Sample Size
200
Recruitment Window Months
21

Geography

Total Number Of Sites
17
Total Number Of Participants
43

France

Earliest CTIS Part Ii Submission Date
27-06-2025
Latest Decision Or Authorization Date
08-07-2025
Processing Time Days
11
Number Of Sites
5
Number Of Participants
13

Sites

Site Name
Institut Bergonie
Department Name
Medical Oncology
Principal Investigator Name
Antoine Italiano
Principal Investigator Email
a.italiano@bordeaux.unicancer.fr
Contact Person Name
Antoine Italiano
Site Name
Institut Paoli Calmettes
Department Name
Oncology
Principal Investigator Name
Cecile Vicier
Principal Investigator Email
vicierc@ipc.unicancer.fr
Contact Person Name
Cecile Vicier
Contact Person Email
vicierc@ipc.unicancer.fr
Site Name
Institut Gustave Roussy
Department Name
DITEP
Principal Investigator Name
Christophe Massard
Principal Investigator Email
christophe.massard@gustaveroussey.fr
Contact Person Name
Christophe Massard
Site Name
Institut De Cancerologie De L Ouest
Department Name
Medical
Principal Investigator Name
Marie Robert
Principal Investigator Email
marie.robert@ico.unicancer.fr
Contact Person Name
Marie Robert
Contact Person Email
marie.robert@ico.unicancer.fr
Site Name
Centre Leon Berard
Department Name
Medical Oncology
Principal Investigator Name
Armelle Vinceneux
Principal Investigator Email
armelle.vinceneux@lyon.unicancer.fr
Contact Person Name
Armelle Vinceneux

Italy

Earliest CTIS Part Ii Submission Date
23-06-2025
Latest Decision Or Authorization Date
08-07-2025
Processing Time Days
15
Number Of Sites
3
Number Of Participants
10

Sites

Site Name
Humanitas Mirasole S.p.A.
Department Name
Oncology
Principal Investigator Name
Matteo Simonelli
Principal Investigator Email
matteo.simonelli@cancercenter.humanitas.it
Contact Person Name
Matteo Simonelli
Site Name
Ospedale San Raffaele S.r.l.
Department Name
Oncology
Principal Investigator Name
Andrea Necchi
Principal Investigator Email
necchi.andrea@hsr.it
Contact Person Name
Andrea Necchi
Contact Person Email
necchi.andrea@hsr.it
Site Name
Istituto Europeo Di Oncologia S.r.l.
Department Name
Oncology
Principal Investigator Name
Giuseppe Curigliano
Principal Investigator Email
giuseppe.curigliano@ieo.it
Contact Person Name
Giuseppe Curigliano
Contact Person Email
giuseppe.curigliano@ieo.it

Belgium

Earliest CTIS Part Ii Submission Date
04-12-2025
Latest Decision Or Authorization Date
23-12-2025
Processing Time Days
19
Number Of Sites
4
Number Of Participants
10

Sites

Site Name
Az Maria Middelares Gent
Department Name
Medical Oncology & hematology
Principal Investigator Name
Christof Vulsteke
Principal Investigator Email
christof.vulsteke@mijnziekenhuis.be
Contact Person Name
Christof Vulsteke
Site Name
Algemeen Ziekenhuis Groeninge
Department Name
Urology
Principal Investigator Name
Karl Lesage
Principal Investigator Email
karl.lesage@azgroeninge.be
Contact Person Name
Karl Lesage
Contact Person Email
karl.lesage@azgroeninge.be
Site Name
Institut Jules Bordet
Department Name
Oncology
Principal Investigator Name
Nuria Kotecki
Principal Investigator Email
nuria.kotecki@hubruxelles.be
Contact Person Name
Nuria Kotecki
Contact Person Email
nuria.kotecki@hubruxelles.be
Site Name
Universitair Ziekenhuis Antwerpen
Department Name
Oncology
Principal Investigator Name
Hans Prenen
Principal Investigator Email
hans.prenen@uza.be
Contact Person Name
Hans Prenen
Contact Person Email
hans.prenen@uza.be

Spain

Earliest CTIS Part Ii Submission Date
10-06-2025
Latest Decision Or Authorization Date
20-01-2026
Processing Time Days
224
Number Of Sites
5
Number Of Participants
10

Sites

Site Name
Hospital Universitario Hm Sanchinarro
Department Name
Centro Integral Oncológico Clara Campall (CIOCC) Phase I trials unit
Principal Investigator Name
Juan Francisco Rodriguez Moreno
Principal Investigator Email
juanfran.rodriguez@startmadrid.com
Contact Person Name
Juan Francisco Rodriguez Moreno
Site Name
Hospital Universitari Vall D Hebron
Department Name
Medical Oncology
Principal Investigator Name
Jaume Capdevila Castillon
Principal Investigator Email
jcapdevila@vhio.net
Contact Person Name
Jaume Capdevila Castillon
Contact Person Email
jcapdevila@vhio.net
Site Name
Hospital Universitario Quironsalud Madrid
Department Name
NEXT Madrid Phase I trials
Principal Investigator Name
Valentina Boni
Principal Investigator Email
vboni@nextoncology.eu
Contact Person Name
Valentina Boni
Contact Person Email
vboni@nextoncology.eu
Site Name
Hospital Quironsalud Barcelona
Department Name
Phase Unit I
Principal Investigator Name
Fabriccio Racca
Principal Investigator Email
fracca@nextoncology.eu
Contact Person Name
Fabriccio Racca
Contact Person Email
fracca@nextoncology.eu
Site Name
Hospital Clinic De Barcelona
Department Name
Medical Oncology
Principal Investigator Name
Begoña Mellado
Principal Investigator Email
BMELLADO@clinic.cat
Contact Person Name
Begoña Mellado
Contact Person Email
BMELLADO@clinic.cat

Sponsor

Primary sponsor

Full Name
Synnovation Therapeutics Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Related trials

Other published trials that may interest you.